The company joins a wave of global pharma companies reshoring operations to strengthen the US supply chain and meet patient ...

As drug development increasingly targets multiple indications, pharma companies must make strategic branding ...

In the final part of his Pharma Commerce video interview, Mark Sawicki, PhD, Cryoport Systems’ president and CEO, predicts ...

The Impact of FDA’s Ban on Compounded GLP-1s A Pharmaceutical Executive article explores how the FDA’s ban on compounded semaglutides—following stabilized supply from Novo Nordisk and Eli Lilly—has ...

Bruce Leuchter, CEO, Neurvati, discusses the vital role of public participation in healthcare policy, highlighting how ...

State Medicaid leaders create a plan to ensure safety, affordability, and equitable access for children and families living ...

In response to the rising importance of real-world evidence (RWE) in showing value to payers beyond traditional clinical trials, key opinion leaders emphasize finding cost-effective approaches, ...